[Changes in the levels and composition of lipoproteins and apolipoproteins of blood plasma in patients with ischemic heart disease after hemosorption].
Prior to and following activated charcoal hemosorption, concentrations of lipids, apolipoproteins AI and B and lipid and protein composition in lipoprotein fractions isolated by ultracentrifugation were determined in the plasma from patients with coronary heart disease. The majority of the patients showed a parallel proportional decrease in plasma atherogenic parameters and all components of very low density lipoproteins and low density lipoproteins, triglycerides in particular. Antiatherogenic parameters, such as high density lipoprotein and apo-AI cholesterol, and all the components in high density lipoprotein subfractions were less reduced. In 19% of the patients, hemosorption failed to affect plasma lipids and apolipoproteins. The findings suggest that, in case of successful hemosorption, apoB-containing lipoproteins are chiefly eliminated as whole complexes from the plasma and that this procedure is most beneficial in hypertriglyceridemia.
Torkhovskaia
T I
TI
Khalilov
E M
EM
Oleĭnik
I A
IA
Kliuchnikova
Zh I
ZhI
Klimov
A N
AN
D001053:Apolipoproteins / Q000032:analysis / Q000097:blood*; D001054:Apolipoproteins A / Q000032:analysis / Q000097:blood; D001055:Apolipoproteins B / Q000032:analysis / Q000097:blood; D002784:Cholesterol / Q000032:analysis / Q000097:blood; D003327:Coronary Disease / Q000097:blood* / Q000628:therapy; D006464:Hemoperfusion; D006801:Humans; D008075:Lipoproteins, HDL / Q000032:analysis / Q000097:blood*; D008077:Lipoproteins, LDL / Q000032:analysis / Q000097:blood*; D008297:Male; D014280:Triglycerides / Q000032:analysis / Q000097:blood
D001053:Apolipoproteins; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol
Izmenenie kontsentratsii i sostava lipoproteidov i apoproteinov plazmy krovi u bo'lnykh ishemicheskoĭ bolez'niu serdtsa posle gemosorbtsii.